Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine.
Front Immunol
; 13: 857779, 2022.
Article
in En
| MEDLINE
| ID: mdl-35371101
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cancer Vaccines
/
Neoplasms
Limits:
Animals
Language:
En
Journal:
Front Immunol
Year:
2022
Document type:
Article
Country of publication:
Switzerland